Search results
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure…
View more
Added:
1 year ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the…
View more
Added:
2 months ago
HFA Congress 2026 — Dr Ida Arentz Taraldsen (Amager and Hvidovre Hospital, Copenhagen University Hospital, Hvidovre, DK) discusses REDOX-AHF, a prospective, randomised, blinded, multicentre pilot trial evaluating restrictive versus liberal oxygenation targets in patients hospitalised with acute heart failure and pulmonary congestion.Although oxygen therapy is widely used in the acute management…
View more
Added:
1 year ago
THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.Dr Marat…
View more
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
1 year ago
HRS 2025 - Contemporary outcomes from implantable devices in non-ischemic cardiomyopathy patients observed more advanced heart failure symptoms in women at the time of ICD implantation, and white women implanted with CRT-D devices had significantly lower ventricular arrhythmia events compared to men of all races and black women implanted with both device types.Dr Valentina Kutyifa (University of…
View more
Added:
9 months ago
HFSA 25 - Aficamten improves excercise capacity compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy in a prespecified analysis of the MAPLE-HCM study.Dr Gregory Lewis joins us to discuss findings from a prespecified cardiopulmonary exercise testing analysis of the MAPLE-HCM trial, which reveals divergent effects between aficamten and metoprolol on exercise performance…
View more
Added:
1 year ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Added:
2 months ago
In this Radcliffe Cardiology Masterclass, Dr Harriette Van Spall (McMaster University, Canada) sits down with cardiology legend Dr Eugene Braunwald (Harvard Medical School, TIMI Study Group) to explore his life, landmark research, and advice for the next generation of cardiovascular clinicians and scientists. This discussion was originally recorded in 2021, and we share it now in remembrance of…
View more
Added:
9 months ago
HFSA 25 - CCM-D was associated with successful defibrillation and symptom improvement in patients with HFrEF at 6 months in the INTEGRA-D Trial.Dr Nir Uriel (NewYork-Presbyterian, Columbia University Irving Medical Center, US) joins us to discuss findings from the Integra-D trial, evaluating a novel implantable device that provides both cardiac contractility modulation and defibrillation…
View more